Prostate Cancer clinical trials in Nevada

5 actively recruiting prostate cancer trials at 5 sites across Nevada.

Data from ClinicalTrials.gov · last refreshed 2026-08-17

Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06136624

Sites in Nevada:

Comprehensive Cancer Centers of Nevada ( Site 0010) — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT03866382

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Cancer and Blood Specialists-Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
Las Vegas Cancer Center-Henderson — Henderson, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…

Sponsor: Candel Therapeutics, Inc.

NCT ID: NCT07332000

Sites in Nevada:

Sheldon Freedman, MD Ltd. — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis

NCT ID: NCT05176483

Sites in Nevada:

Exelixis Clinical Site #55 — Las Vegas, Nevada

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Cancer and Blood Specialists-Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
Las Vegas Cancer Center-Henderson — Henderson, Nevada

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17